Cover Image
Market Research Report

Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy

Published by BCC Research Product code 882253
Published Content info 21 Pages
Delivery time: 1-2 business days
Price
Back to Top
Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
Published: July 3, 2019 Content info: 21 Pages
Description

Report Highlights:

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.

Report Includes:

  • An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
  • Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
  • Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
  • Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
  • Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications
Table of Contents
Product Code: BIO129A

Table of Contents

Chapter 1: The Emergence of Cell Therapy Using TILs

  • Introduction
  • Analyst's Credentials
  • Related Reports

Chapter 2: Development of TIL Therapies in Metastic Melanoma

  • TIL Generation Explained
  • Importance of Lymphodepletion
  • Role of Interleukin-2
  • Feasibility of TIL as a Mainstream Treatment Option

Chapter 3: Development of TIL Therapies in Other Tumour Types

  • Cervical Cancer
  • Ovarian Cancer
  • Kidney Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancers

Chapter 4: Clinical Development of TIL Therapies

  • Lifileucel (LN-144), Iovance Biotherapeutics
  • LN-145, Iovance Biotherapeutics
  • TILT-123, TILT Biotherapeutics
  • Optera Therapeutics Corp.
  • Other Centers Conducting TIL Research
  • Future Perspectives for TIL

Chapter 5: References

List of Tables

  • Table 1: TILs and Tumor Specific Antigens
  • Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
  • Table 3: Clinical Trials Studying TIL Therapies

List of Figures

  • Figure 1: Generation of Tumor Infiltrating Lymphocytes
  • Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
  • Figure 3: TILT Biotherapeutics Development Pipeline
Back to Top